Interna Therapeutics has entered a research collaboration with Daiichi Sankyo, through the Daiichi Sankyo Research Institute Boston, to evaluate Interna’s Molecular Nano Motor (MNM) technology as a delivery enhancer for targeted therapeutic modalities. The agreement focuses on integrating MNM molecules with targeting approaches to improve intracellular delivery, functional activity, and overall therapeutic performance across selected programs. The collaboration structure includes a framework that may be expanded to broader research activities and additional programs depending on research outcomes.
Interna’s MNM platform is designed to support efficient intracellular delivery of diverse therapeutic cargos, including nucleic acids and other macromolecules, without relying on traditional delivery systems. According to the company, the approach aims to enhance intracellular access and tissue penetration to improve the performance of targeted therapies across multiple indications. The collaboration adds to Interna’s existing portfolio of partnerships with global pharmaceutical companies.
The initial phase of the Interna–Daiichi Sankyo collaboration will focus on preclinical evaluation of MNM-enabled delivery in selected programs. Financial terms of the agreement were not disclosed.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!